Thera-SAbDab

CEMIPLIMAB

>   Structural Summary
TherapeuticCemiplimab
TargetPDCD1
Heavy ChainEVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedInovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sidney Kimmel Cancer Center, SillaJen Biotherapeutics, University of Texas M. D. Anderson Cancer Center
Conditions ApprovedSquamous cell cancer
Conditions ActiveCervical cancer, Non-small cell lung cancer, Basal cell cancer, Oropharyngeal cancer, Prostate cancer, Fallopian tube cancer, Glioblastoma, Multiple myeloma, Ovarian cancer, Peritoneal cancer, Solid tumours, B-cell lymphoma, Cancer, Head and neck cancer, Malignant melanoma, Renal cell carcinoma
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]